Janux Therapeutics, Inc. (JANX) News
Follow Janux Therapeutics, Inc. (JANX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Janux Therapeutics Reports Quarterly Results for Quarter Ended September 30
EQUITY | Nov 05, 2026, 10:33 PM UTC
M
Janux Therapeutics Q3 Net Loss Narrows on Lower R&D Expenses
EQUITY | Nov 05, 2026, 09:44 PM UTC
M
Janux Therapeutics Reports Third-Quarter 2026 Financial Results
Janux reported financial results for the quarter ended September 30, 2026, and provided a business update.
EQUITY | Nov 05, 2026, 09:05 PM UTC
M
Janux Q3'26 Revenue Estimate Is 8.03M USD
Janux Therapeutics is scheduled to report Q3'26 results on November 10; revenue is estimated at 8.03 million USD and EPS at (0.47) USD. The announcement time is not specified.
EQUITY | Nov 03, 2026, 12:01 PM UTC
L
Wolfe Research upgrades JANX to Outperform, sets $23 target
Wolfe Research upgrades JANX from Peerperform to Outperform and assigns a $23.00 price target, with no catalyst supplied in the alert.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
Analysts raise ratings on ALGT, CLS, DRI, JANX and PHM
A wire item says analysts upgraded ALGT to Strong Buy at Raymond James, CLS to Buy at UBS, and DRI, JANX and PHM to Outperform at Baird or Wolfe.
EQUITY | Aug 24, 2026, 10:50 AM UTC
L
Wolfe Research upgrades JANX to Outperform, sets $23 target
Wolfe Research upgrades JANX to Outperform from Peerperform and sets a $23 price target.
EQUITY | Aug 24, 2026, 10:15 AM UTC
M
JANX: Truist Assumes Buy
Truist Securities analyst assumes Janux Therapeutics with a Buy rating and lowers Price Target to $26
EQUITY | Jun 25, 2026, 02:10 PM UTC